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Summary Different dosing regimens for vancomycin are in clinical use: intermit-
tent infusion and continuous administration. The intention of using these different
dosing regimens is to reduce toxicity, to achieve target levels faster and to avoid
treatment failure. The aim of this phase IV study was to compare safety and effec-Therapeutic drug
monitoring
tiveness in both administration regimens. The study was conducted in 2010 and 2011
in three postoperative intensive care units (ICUs) in a tertiary care university hos-
pital in Berlin, Germany. Adult patients with vancomycin therapy and therapeutic
drug monitoring were included. Out of 675 patients screened, 125 received van-
comycin therapy, 39% with intermittent and 61% with continuous administration.
Patients with continuous administration achieved target serum levels signiﬁcantly
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earlier (median day 3 versus 4, p = 0.022) and showed fewer sub-therapeutic serum
levels (41% versus 11%, p < 0.001). ICU mortality rate, duration of ICU stay and dura-
tion of ventilation did not differ between groups. Acute renal failure during the ICU
stay occurred in 35% of patients with intermittent infusion versus 26% of patients
with continuous application (p = 0.324). In conclusion, continuous administration of
vancomycin allowed more rapid achievement of targeted drug levels with fewer sub-
levels observed. This might indicate that patients with more
er variability in renal function could beneﬁt from this form
dulaziz University for Health Sciences. Published by Elsevier
ed.
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to improve guideline adherence in critically ill
patients [15].therapeutic vancomycin
severe infections or high
of administration.
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Limited. All rights reserv
Introduction
The glycopeptide vancomycin was introduced into
the anti-infective armamentarium in the 1950s,
before modern pharmacodynamic and pharmacoki-
netic methods were established to guide dosing
practices [1,2]. More than 50 years of routine
usage and research followed and the agent has
been well characterized. Recommendations have
changed over time, and higher vancomycin trough
serum levels are desired, especially in severe
infection, depending on the pathogen identiﬁed.
Although widely debated, there are recommenda-
tions that trough levels of between 15 and 20mg/L
should be achieved to prevent development of
resistance and to achieve sufﬁcient serum tissue
levels [3]. Nevertheless, it remains a clinical chal-
lenge to merge all available patient-based data,
e.g., location of infection, weight, glomerular ﬁl-
tration rate, co-morbidities and co-medication,
into suitable dosing guidelines and thereby use this
information to achieve appropriate trough serum
levels [4]. Recently, the frequency of therapeutic
drug monitoring (TDM) and appropriate vancomycin
utilization were veriﬁed in a prospective trial
evaluating the clinical and educational value of
additional intensive care unit (ICU) chart reviews
by clinical pharmacists [5]. In contrast, nomograms
have been analyzed with the intention to improve
dosing patterns, but they failed to help in achieving
sufﬁcient vancomycin serum levels [6]. Similarly,
using dosing recommendations provided by the
current vancomycin product information has been
demonstrated to be even worse for obtaining target
serum levels [7]. Consequently, TDM is recom-
mended to guide vancomycin therapy [3], and data
from a recent clinical trial showed that repeated
measurements increase the safety of target serum
levels in a subset of medical ICU patients [8].
Vancomycin interacts with cell wall synthesis in
gram-positive bacteria, and there has been con-
troversy regarding the optimal pharmacological
P
A
hescription [9]. Some authors have reported time-
ependent bacterial killing properties, and others
ave favored concentration-dependent models for
ancomycin. Two dosing regimens are repeat-
dly discussed with the intention of optimizing
ancomycin serum levels and subsequent patient
utcome. Intermittent administration regimens
ay be beneﬁcial with regard to possible post-
ntibiotic effects described in several experimental
ettings, without being deﬁnitively proven in clin-
cal studies [10—12]. Continuous infusion may
chieve target plasma levels faster. This dosing
egimen was described to achieve more stability
n the area under the serum concentration—time
urves (AUC) combined with the possibility to mea-
ure serum levels earlier [12—14]. Clinical data
omparing both dosing regimens are limited and
here remains uncertainty regarding optimal dos-
ng strategies in ICU patients. In this context, this
tudy was performed to evaluate the effectiveness
nd safety of the two different dosing regimens for
ancomycin for empirical anti-infective treatment
n surgical ICU patients.
aterials and methods
tudy design and setting
his trial represents a phase IV study, including
urgical patients treated in three ICUs at Charité
niversity hospital, a tertiary medical care cen-
er in Berlin, Germany. The study is based on a
econdary analysis of prospectively obtained data
rom a larger interventional clinical trial on antibi-atients, data collection and measurement
dult patients were screened for study inclusion by
aving an ICU stay of at least 36 h. Inclusion criteria
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dffects of different dosing regimens on vancomycin
or the study population were the administration of
ntravenous vancomycin during the ICU stay at more
han one dose and therapeutic drug monitoring per-
ormed, excluding patients with oral vancomycin
herapy or single shot antibiotic therapy in the con-
ext of a previous surgery.
All study wards used standards for vancomycin
herapy, providing detailed information regarding
oth administration methods (Table 1). To assess
verall implementation rates as a surrogate for the
pplicability of given recommendations, all therapy
ays were analyzed consecutively for each patient.
ays were deﬁned as adherent to recommenda-
ions when (A) measured vancomycin serum levels
ere within predeﬁned limits and (B) vancomycin
osing was promptly adapted depending on mea-
ured serum levels according to the drug monitoring
ecommendations. Adherence to the recommenda-
ions was expressed as rate of adherent days in
elation to all days with vancomycin for every con-
ecutive patient. Acute renal failure was deﬁned
sing RIFLE criteria for injury, failure or loss [16].
uration of ventilation was compared for patients
ith any mechanical ventilation via endotracheal
ntubation or tracheotomy as the time of active
entilator support.
The primary study aim was to evaluate van-
omycin serum levels after induction of systemic
ntravenous vancomycin therapy, depending on the
dministration regimen chosen. Secondary study
ims were to describe differences in the clinical
ourses associated with both application strategies.
herapeutic drug monitoring (TDM) for
ancomycin
or all study wards, therapeutic and diagnostic rec-
mmendations regarding anti-infective therapy are
mplemented based on a computerized decision-
upport system called ABx [15,17,18]. This program
lso provides detailed information for dosing and
herapeutic drug monitoring (TDM) for vancomycin
see Table 1). Information provided was consented
n interdisciplinary rounds based on national and
nternational guidelines for vancomycin admin-
stration [3]. The attending ICU physicians in
harge made the decision of which speciﬁc dosing
egimen was applied—–intermittent or continuous
ancomycin administration—–independently from
his observational study project.
Serological vancomycin testing was performed
or routine TDM in every patient with vancomycin
herapy, using standard competitive homogenous
nzyme immunoassays in our central labora-
ory. For patients with intermittent vancomycin
dministration, determination of the ﬁrst trough
evel is recommended at least before the 4th
m
c
t
Iget levels 357
dministration, compared with continuous admin-
stration, for which the ﬁrst drug monitoring is
ecommended 24—36 h after initiation. Serum van-
omycin thresholds have recently been widely
ebated [3] and levels of 15—20mg/L were sug-
ested to achieve higher vancomycin levels at the
ites of severe infections. As higher thresholds have
lso been associated with higher nephrotoxicity
19] in patients with less severe infections, a more
areful dosing strategy has been suggested [3,20].
or the purposes of this study and in concordance
ith the guidelines [3,20], a serum level of at least
0mg/L was used as the target, assuming that this
s the minimally effective dose on infection sites,
nd the maximum dose was 20mg/L, to provide a
oxicity margin [3].
tatistical analysis and ethic review
esults are expressed in proportions, with the medi-
ns and 25—75% quartiles or arithmetic means and
tandard deviations given as appropriate. Depend-
ng on the scale levels and distributions, tests for
tatistical signiﬁcance were performed with the
wo-tailed Student’s T-, Wilcoxon—Mann—Whitney-
r Fisher exact-tests. A p-value of <0.05 was con-
idered to be signiﬁcant. Analyses of time courses
ere visualized using cumulative incidence curves
nd the generalized Wilcoxon test was used to
nalyze the statistical signiﬁcances of effects. Cal-
ulations were conducted with PASW, Version 19
SPSS Inc., USA).
The clinical study was approved by the local
thics Review Board and the data safety authorities.
ue to the observational nature of the evalua-
ion, the Ethics Review Board waived the need for
nformed consent.
esults
atient characteristics and administration
egimen
cohort of 675 consecutively admitted ICU patients
ere screened. One hundred twenty-ﬁve patients
eceived intravenous vancomycin, comprising the
tudy population. Out of these, 49 (39%) were
reated with intermittent infusion, versus 76 (61%)
ith continuous application. Both treatment groups
id not differ in terms of gender, age or co-
orbidities. Furthermore, scoring systems showed
omparable values for surrogate values indicating
he severity of disease at admission. During their
CU stays, patients in the group with intermittent
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Table 1 Recommendations for therapeutic drug monitoring for vancomycin therapy based on a computerized
decision-support system implemented on the study wards [17,18].
1. Dosing regimens for initial vancomycin therapy:
1.1. Intermittent administration
In adults: 500mg vancomycin every 6 h given over 1 h or 1 g every 12 h, given over 1 h. For empirical
therapy, a full loading dose is recommended independent from renal function.
1.2 Continuous administration
Using continuous vancomycin administration, targeted drug levels are more easily attained. Vancomycin
should be administered continuously by the central line only, as it may irritate vein surfaces.
Initiation of therapy with 1 g vancomycin as an infusion given over 1 h, followed by
• in patients with normal renal function, 2 g vancomycin continuously infused during 24 h [e.g., 1 g of
vancomycin in 50mL of solution with a rate of 4.2mL/h in a perfusion pump];
• in patients with impaired renal function and creatinine clearances of <50mL/min, 1 g vancomycin
continuously over 24 h [e.g., 1 g of vancomycin in 50mL of solution with a rate of 2.1mL/h in a perfusion
pump];
• in patients with impaired renal function and creatinine clearances of <20mL/min, 500mg vancomycin
continuously during 24 h [e.g., 1 g of vancomycin in 50mL of solution with a rate of 1mL/h in a perfusion
pump]
2. TDM for initial vancomycin therapy:
2.1. Intermittent administration
Trough level measurement is superior to peak level monitoring for therapeutic drug monitoring of
vancomycin. The ﬁrst trough level should be measured just before the 4th administration of intermittent
vancomycin infusion. After obtaining blood for laboratory testing, administration of vancomycin should be
continued until results of the TDM are available. Doses should be adapted when the TDM results suggest
higher or lower trough levels than targeted.
Targeted trough levels: 10—15mg/L; for severe infection: 15—20mg/L.
2.2 Continuous administration
TDM should be initiated after 24—36 h of continuous vancomycin administration. Doses should be
adapted when TDM results suggest higher or lower trough levels than targeted. If sufﬁcient therapeutic
drug levels are detected, further routine TDM should be initiated every week of therapy.
Targeted levels: 15—20mg/L.
In case of changes in renal function or co-medication with nephrotoxic drugs, more frequent TDM is
V
v
T
p
c
3
d
t
a
w
t
g
s
4
6recommended.
vancomycin infusion developed urogenital- and
central venous catheter-related infections, as well
as infections of soft tissues, signiﬁcantly more often
than the group with continuous administration. The
duration of vancomycin therapy was signiﬁcantly
longer in the continuous-infusion vancomycin pop-
ulation. All basic characteristics are displayed in
Table 2.
Vancomycin therapy adherence
The overall mean implementation rate of van-
comycin therapy recommendations was 69% (95%
CI 65—73%). Comparing both dosing regimens for
the intermittent vancomycin infusion population, a
median of 67% of all administration days (25—75%
quartiles 50—88) were found to be adherent with
the given recommendations versus 71% (25—75%
quartiles 57—89) in the group with continuous appli-
cation (p = 0.244).
a
c
T
lancomycin serum levels and time course of
ancomycin therapy targets
he time courses of vancomycin levels in both
opulations are displayed in Fig. 1. The ﬁrst van-
omycin measurement was performed on ICU day
± 5 in the group with intermittent infusion, versus
ay 2± 2 in the group with continuous applica-
ion (p = 0.007). Comparing all TDM values, at least
single sub-therapeutic trough level (<10mg/L)
as observed in 75.5% of patients in the intermit-
ent group, compared with 30.3% in the continuous
roup (p < 0.001). In contrast, at least a single
upra-therapeutic level (>20mg/L) was found in
4.9% of patients in the intermittent group and in
3.2% in the continuous group (p = 0.065).
One main therapeutic goal for the initialdministration of vancomycin is to achieve sufﬁ-
ient serum levels in the ﬁrst hours of therapy.
herefore, we analyzed the duration until serum
evels reached the reference levels of 10—20mg/L
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Table 2 Patient characteristics and therapies. Binary variables are given in percentages (%); continuous variables
are given in medians (with 25—75% quartiles) or means (with ±standard deviations).
Intermittent
vancomycin group
N = 49
Continuous vancomycin
group
N = 76
Signiﬁcance level
Gender N (% females) 15 (31%) 31 (41%) ns
Weight (kg) 80 (70—90) 70 (60—90) ns
Age (years) 67 (48—75) 60 (50—70) ns
Co-morbidities (%)
Cardiac 67% 61% ns
Pulmonary 41% 30% ns
Vascular 35% 38% ns
Hepatic 18% 15% ns
Renal 41% 32% ns
Metabolic 47% 36% ns
Neurological 29% 20% ns
Immunosuppression 18% 17% ns
Infections (%)a
Pneumonia 78% 72% ns
Endocarditis 12% 8% ns
Urogenital 25% 11% 0.047
ZNS 12% 22% ns
Abdomen 18% 15% ns
Catheter-related 49% 24% 0.006
Bones and joints 12% 5% ns
Soft tissues 31% 9% 0.003
Unknown focus 7% 2% ns
SAPS II on admission 51 (40—69) 47 (35—61) ns
SOFA on admission 9 (5—13) 7 (3—11) ns
TISS-28 on admission 37 (28—50) 40 (31—46) ns
APACHE on admission 25 (19—33) 24 (17—28) ns
Duration of vancomycin therapy 5 (3—8) 7 (4—11) 0.009
Proportion of drug serum levels
below reference TDM in
mean± SDb
41± 37% 11± 23% <0.001
Proportion of drug serum levels
above reference TDMb
19± 28% 36± 37% 0.010
a per p
; for
TDM
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DInfections during ICU stays; more than one focus possible
b Reference TDM for intermittent application: 10—20mg/L
below 10mg/L or above 20mg/L is divided by total number of
ancomycin. The resulting cumulative incidence
urves are displayed in Fig. 2, showing faster
chievement of reference levels for the continuous
dministration method. Patients with continuous
dministration achieved target serum levels signif-
cantly earlier, on median day 3 (25—75% quartiles:
—7) versus day 4 (25—75% quartiles: 3—8) in the
ntermittent group (p = 0.022).
linical course of patients
n total, 38 (78%) of the patients with intermittent
ancomycin infusion survived, whereas 61 (80%) of
he patients with continuous administration sur-
ived (p = 0.822).
Acute renal failure during the ICU stay was
etected in 35% of the patients with intermittent
T
w
eatient.
continuous application: 15—20mg/L. Number of TDM results
measurements. SD, standard deviation.
nfusion versus 26% in the group with continuous
pplication (p = 0.324).
Median ICU stay was 16 days (25—75% quar-
iles: 8—35) in the intermittent group versus 20
ays (25—75% quartiles: 11—27) in the continu-
us group (p = 0.729). The duration of ventilation
lso did not show differences, with 256 h (25—75%
uartiles: 31—748) in the intermittent group versus
65 h (25—75% quartiles: 99—569) in the continuous
opulation (p = 0.424).
iscussionhe most important ﬁnding of this study is that,
ith continuous administration of vancomycin, ref-
rence serum levels are achieved earlier compared
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Figure 1 Vancomycin serum levels compared for intermittent versus continuous administration over 21 days; data
showing median and interquartile ranges; */** indicating the
Figure 2 Cumulative incidence curves showing dura-
tion (days) until reference serum levels were achieved
with vancomycin serum thresholds of 10—20mg/L. In the
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patients [8]. In addition, we observed high ratescontinuous group, the serum levels were achieved signif-
icantly earlier (p = 0.019).
with the intermittent administration regimen. Fur-
thermore, in patients with continuous application
of vancomycin, TDM less frequently revealed serum
levels below the 10mg/L threshold but more often
showed serum levels above 20mg/L.
Regarding baseline characteristics, the study
population was well balanced for most variables
as well as for severity of disease. There were only
small differences in infections observed during the
course of the ICU stay, but the overall distribu-
tion of infections was in concordance with other
o
c
vnumber of patients measured.
ublications in different settings [21,22]. Therapy
ecommendations for vancomycin were applied suf-
ciently with approximately 70% of all patient days
eing adherent to recommendations, with slightly
ore adherence in the continuous group. Based on
revious studies, adherence to therapy recommen-
ations can be beneﬁcial for patients [23—25], and
threshold of 70% was deﬁned as the quality target
or the implementation of our intensive care unit
herapy standards.
With special emphasis on therapy initiation,
umulative incidence analyses made it obvious that
he continuous dosing regimen achieved target ref-
rence levels signiﬁcantly earlier. This might be
ne of the most remarkable aspects of this ther-
py form, as the time to achieve appropriate
overage of pathogens was found to be one of
he key interventions in sepsis therapy, especially
or severe infections [26]. In this situation, the
ositive effects of high initial doses on the out-
omes of infections have to be weighed against the
isks of vancomycin-associated kidney failure [19].
onsequently, therapy targets have to be based
n individual co-morbidities and possible alterna-
ive therapy options. In our study, TDM results
ore often showed serum levels above the 20mg/L
hreshold for patients with continuous vancomycin
reatment, but this was not paralleled by higher
ates of acute kidney injury. Similar results were
bserved in a study by Saugel et al. in medical ICUf TDM levels below the 10mg/L threshold, espe-
ially in the group with intermittent infusion of
ancomycin.
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Gffects of different dosing regimens on vancomycin
Low antibiotic serum levels have been attributed
s a risk factor for resistance development and
herefore should be avoided [20]. This problem
as also described for continuous vancomycin
pplication and can be improved with an ini-
ial vancomycin loading dose, as shown in the
tudy of Saugel et al. [8]. However, the spe-
iﬁc reference thresholds remain under discussion
8]. Although some conclusions have been drawn
rom study data and are introduced into treat-
ent recommendations [3], evidence for a speciﬁc
evel is limited [27]. Further discussion is ongoing
elated to the assumed pharmacological mechanism
f vancomycin, with some authors pronouncing
ime dependent [9] versus — at least partly —
oncentration-dependent efﬁcacy of vancomycin
28]. Based on current evidence summarized in
he guidelines [3], vancomycin serum targets are
uggested to be tailored based also on ﬁndings
rom microbiology. Therefore, the area under the
urve (AUC) for vancomycin serum concentrations
easured is related to the minimal inhibitory
oncentration (MIC) of the underlying pathogen.
owever, repeatedly sampling vancomycin serum
evels is rarely possible, and serum trough levels
f 15mg/L vancomycin were described to be suf-
cient to achieve the target ratio of AUC/MIC of
00.
Interestingly, continuous administration was
pplied longer in our study compared with inter-
ittent administration. Additionally, for a patient
f body weight 80 kg and normal renal function,
oses applied within the ﬁrst 24 h were 2 g for inter-
ittent exposure versus 3 g of continuous exposure.
he related apprehension for cumulative renal tox-
city is contradicted by our ﬁnding of reduced rates
f renal impairment with continuous vancomycin
herapy along with comparable ICU mortality rates.
t is critical to independently evaluate renal impair-
ent due to the clinically well-known fact that it is
mpossible to decide upon underlying causality and
hat severe infection can itself lead to organ failure
19,29]. Principally, intermittent vancomycin dos-
ng, as described in Table 1, could also be adapted
sing an initial higher loading dose, or the ﬁrst
osing interval could be reduced, to increase the
verall drug exposure in these patients. In our data
et, we were not able to assess such alternative
osing patterns with the intermittent dosing strat-
gy and further studies are required to assess such
ptions.
One major critique of this study is relatedo its observational nature, thus inheriting a
igher variability of dosing compared with ran-
omized controlled interventional studies. In this
ontext, choice of antibiotic therapy as well as
N
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dministration regimen was the responsibility of
he ICU physician. Consequently, patients were non-
andomly assigned to a speciﬁc study group. This
bservational study was performed as a secondary
nalysis of prospectively obtained data and is there-
ore also limited to the variables evaluated in the
rial and to the number of patients observed [25].
s an example, it would have been interesting to
nalyze TDM results in relation to body weight, but
hese variables were not available in a signiﬁcant
umber of patients. On the other hand, this phase
V clinical study’s data reﬂect the current best
tate of practice independently of selected popu-
ations or with speciﬁc interventions not available
n the clinical routine. Over past decades, optimal
erum levels for vancomycin therapy have contin-
ed to be changed related to the ongoing evaluation
f this valuable drug [3]. Furthermore, minimal
nhibitory concentrations for pathogens (MICs) were
ot included in this analysis. This information was
ot incorporated, as vancomycin therapy often has
o be initiated empirically to cover the relevant
uspected pathogen spectrum without results from
icrobiological analyses, and recommendations are
rimarily given for initial therapy. An MIC creep for
ancomycin has also been described lately, poten-
ially questioning the future use of vancomycin as
he prevalence of higher MICs increases, but this
lso supports the need for more rapid achievement
f target levels [30,31].
onclusion
ontinuous infusion of vancomycin might be helpful
o achieve determined target levels, but prospec-
ive trials are needed to demonstrate a potential
atient beneﬁt, especially incorporating the focus
f infection and the MICs of pathogens.
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